SWOG clinical trial number
CTSU/R1010

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma

Closed
Phase
III
Abbreviated Title
Ph III HER-2 Esophageal with Trimodality + Trastuzumab
Status Notes
This study is closed to accrual to STEP 1 effective 11/10/15.
Activated
09/01/2011
Closed
11/10/2015
Participants
CTSU

Research committees

Gastrointestinal Cancer
Symptom Control and Quality of Life

Treatment

Paclitaxel Carboplatin Trastuzumab RT

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

SWOG has endorsed this trial via the Endorsement Plus Option. Therefore, institutions holding dual memberships in SWOG and RTOG may credit either Group for enrollments, provided the credited investigator is a member of the credited Group.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2022

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

H Safran;K Winter;D Ilson;D Wigle;T DiPetrillo;M Haddock;T Hong;L Leichman;L Rajdev;M Resnick;L Kachnic;S Seaward;H Mamon;D Diaz Pardo;C Anderson;X Shen;A Sharma;A Katz;J Salo;K Leonard;J Moughan;C Crane Lancet Oncology Feb;23(2):259-269

PMid: PMID35038433

Other Clinical Trials

SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Research Committee(s)
Symptom Control and Quality of Life
Activated
08/16/2021
Accrual
22%
Open
Phase
II
SWOG Clinical Trial Number
S1600

A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Research Committee(s)
Symptom Control and Quality of Life
Genitourinary Cancer
Activated
02/21/2019
Accrual
74%
Open
Phase
III
SWOG Clinical Trial Number
S1614

Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors

Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
02/21/2019
Accrual
1%
Open